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CBP and P300 regulate distinct 
gene networks required for human 
primary myoblast differentiation 
and muscle integrity
Lucas Fauquier1, Karim Azzag1,2, Marco Antonio Mendoza Parra3, Aurélie Quillien1, 
Manon Boulet1,4, Sarah Diouf1,4, Gilles Carnac5, Lucas Waltzer1,4, Hinrich Gronemeyer3 & 
Laurence Vandel  1,4
The acetyltransferases CBP and P300 have been implicated in myogenesis in mouse immortalized 
cell lines but these studies focused only on the expression of a handful of myogenic factors. Hence, 
the respective role of these two related cofactors and their impact at global scale on gene expression 
rewiring during primary myoblast differentiation remain unknown. Here, we characterised the gene 
networks regulated by these two epigenetic enzymes during human primary myoblast differentiation 
(HPM). We found that CBP and p300 play a critical role in the activation of the myogenic program and 
mostly regulate distinct gene sets to control several aspects of HPM biology, even though they also 
exhibit some degree of redundancy. Moreover, CBP or P300 knockdown strongly impaired muscle cell 
adhesion and resulted in the activation of inflammation markers, two hallmarks of dystrophic disease. 
This was further validated in zebrafish where inhibition of CBP and P300 enzymatic activities led to cell 
adhesion defects and muscle fiber detachment. Our data highlight an unforeseen link between CBP/
P300 activity and the emergence of dystrophic phenotypes. They thereby identify CBP and P300 as 
mediators of adult muscle integrity and suggest a new lead for intervention in muscular dystrophy.
Transcriptional regulation of gene expression is the primary mechanism controlling cellular processes such as cell 
proliferation and differentiation. It is a highly coordinated process that requires the recruitment of transcription 
factors (TF), chromatin modifying factors and the basal transcriptional machinery to regulatory regions of the 
genome. Among chromatin-modifying enzymes, the cAMP response element-binding protein (CREB) binding 
protein (also called CBP, CREBBP or KAT3A) and the highly related protein P300 (also known as KAT3B) har-
bour a histone acetyltransferase (HAT) activity and activate transcription by acetylating specific lysine residues 
on histones but also on non histone proteins such as TF or transcription coregulators1,2. Both CBP and P300 are 
involved in multiple signalling pathways and various biological processes as they are recruited to their target 
genes via a wide spectrum of transcription factors, more than 400 having been identified to date (for a review3).
Consistent with their function as transcriptional co-activators, CBP and P300 play a crucial role in devel-
opment. Mice harbouring a homozygous deletion of either P300 or Cbp die at early stage of embryonic devel-
opment and exhibit distinct phenotypes, indicating that these two factors display different functions in vivo4,5. 
Interestingly though, P300+/–/Cbp+/– double heterozygous mice die before birth, suggesting that CBP and P300 
also exhibit some functional redundancy4. In contrast to the in vivo situation, most studies with tissue culture 
cells suggested similar functions for P300 and CBP, and their distinctive roles remain largely elusive. For instance, 
ChIP-sequencing analyses showed that the vast majority of the genes bound by CBP and P300 were common 
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in cell cycle synchronized cells6. Of note though, another study trying to address the functional connections 
between genome-wide recruitment of CBP and gene expression showed that the majority of CBP recruitment 
events do not stimulate nearby genes7. Moreover, higher order chromosome structures mediated by P300 and 
CBP are important in maintaining embryonic stem cell (ESC)-specific gene expression by promoting crosstalks 
among multiple distal and proximal enhancers with promoters8. Hence, while ChIP-sequencing is classically used 
to define CBP or P300 binding repertoires, it is a poor proxy to identify the gene networks controlled by these two 
factors and to characterise their biological activities.
While CBP and/or P300 were shown in cell-based assays to act as co-activators for several transcription fac-
tors critically involved in myogenesis, such as MyoD, Myogenin or Mef2C9–12, their respective function in this 
process remains poorly characterised. Vertebrate myogenesis requires the cooperation of the myogenic regula-
tory factors (MRFs) MyoD, Myf5, Mrf4 and Myogenin13, and the members of the Myocyte-enhancer factors 2 
(Mef2) family, with chromatin remodelling or modifying enzymes (for reviews,14–17. Myoblast differentiation is a 
sequential process that starts by the withdrawal from the cell cycle, followed by the expression of factors involved 
in the muscle specific transcriptional program. Thereafter, myoblasts undergo morphological changes by first 
elongating, before fusing into multinuclear myofibers. Hence, during this process, myoblasts undergo dramatic 
changes in morphology and gene expression.
To date, most studies aimed at analyzing the impact of CBP or P300 on myogenesis used C2C12 cells, an 
immortalised cell line derived from mouse muscles, and focused on the expression of a handful of myogenic fac-
tors9–12. However, the respective role(s) of CBP and P300 during myogenesis has neither been addressed at global 
scale or in humans. Therefore here we used human primary myoblasts to characterise the phenotypes associated 
with CBP and/or P300 knockdown and to identify the gene networks regulated by these two co-activators.
We found that the majority of the deregulated genes are divergent between CBP and P300, showing for the 
first time the respective consequences of their downregulation at genome-wide expression level in the differentia-
tion of human primary myoblasts. Our data also indicate that CBP and P300 are complementary to each other by 
acting on distinct genes belonging to the same pathways. In particular, we found that besides their requirement 
for the activation of the muscle gene expression program, they regulate the expression of various extracellular 
signalling pathways, cell cycle factors or replication complexes. Interestingly, they also concur to the expression 
of different cell adhesion complexes, including components of the dystrophin-glycoprotein complex and the α7β1 
integrin complex, which are essential for the maintenance of skeletal muscle integrity and are mutated in human 
muscle disorders (for a review18). Accordingly, P300 as well as CBP were both required for muscle cell attachment. 
This finding was further validated using zebrafish as a model system in which decreased CBP and P300 HAT 
activity led not only to the downregulation of the homologous genes implicated in ECM/muscle interaction but 
also to a dystrophic-like phenotype. Our results thus indicate that CBP and P300 are both crucial for proper adult 
myogenesis in human and act primarily via distinct though converging gene networks. Finally, we propose that 
modulation of CBP and P300 activity could be implicated in muscular dystrophy.
Results
CBP and P300 knockdowns affect human primary myoblast differentiation. Human primary 
myoblasts (HPMs) were used to study the respective involvement of CBP and P300 in myogenesis. HPM dif-
ferentiation can be induced by serum starvation when cells reach confluence and this process is accompanied 
by striking phenotype changes: at 24 h after induction of differentiation, cells elongate, then align to each other 
at around 48 h to finally fuse to form myotubes from 72 h onwards (Fig. 1a). To monitor this process, we also 
assessed the expression of several molecular markers by Western blot and by RT-qPCR (Fig. 1b,c). Specifically, 
expression levels of the early myogenic transcription factors MYF5 and MYOD decreased during differentiation 
while expression of the later myogenic factors MYOG and MEF2C or of the differentiation markers Myosin 
Heavy Chain (MHC) and Creatine Muscle Kinase (CKM) was strongly enhanced during this process (Fig. 1b,c). 
CBP and P300 were both expressed in proliferating and differentiating myoblasts but exhibited different dynam-
ics i.e. while CBP expression decreased during differentiation both at protein and RNA levels, P300 protein and 
transcript showed a transient increase at 24 h and 48 h (Fig. 1b,c).
In order to assess the function of CBP and P300 in myogenic differentiation, sub-confluent HPMs were trans-
fected with either control or specific siRNAs directed against CBP or P300 mRNAs (hereafter called siCBP and 
siP300) before induction of differentiation by serum starvation. The phenotypes of HPMs transfected with the 
various siRNAs were analyzed at different time points. While cells transfected with control siRNAs underwent 
myogenic differentiation similarly to non-transfected (NT) cells, those transfected with either siCBP or siP300 
showed defects especially from 72 h onwards post-transfection i.e. 48 h after differentiation induction (Fig. 2a). 
Indeed, following CBP or P300 knockdown, HPMs elongate, align with each other and form myotubes/myofibers 
but detach thereafter from the petri dish when the first contractions are observed so that at late time of differ-
entiation only a minority of differentiated cells remain attached (Fig. 2a). CBP and P300 knockdowns were con-
firmed by Western blot and RT-qPCR, each siRNAs specifically affecting the expression of its target with a slight 
compensatory effect between CBP and P300 (Fig. 2b). Of note, similar phenotypes and effects were observed 
using two other sets of siRNAs directed against CBP or P300 mRNA (Supplementary Fig. S1a,b). In parallel, we 
assessed by RT-qPCR whether the expression of key myogenic transcription factors and differentiation markers 
was affected (Fig. 2c). Both siCBP and siP300 impaired the increase of MEF2C, CKM and MHC expression at late 
times of differentiation. In contrast, they had distinct impacts on the expression of MYOD, which was increased 
by siCBP but not affected by siP300, and of MYOG, which was downregulated by siP300 only (Figs 2c and S1c). 
Importantly, similar results were obtained after CBP or P300 knockdown in HPMs purified from biopsies from 
two independent donors, indicating that the observed effects were not specific of a given donor but reflect the 
genuine function of CBP an P300 in HPM differentiation (Supplementary Fig. S2). In sum, these results indicate 
that HPMs deprived of CBP or P300 initiate myogenesis but do not progress normally toward differentiation 
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and ultimately show strong adhesion defects. These data also suggest that CBP and P300 regulate differentially 
myogenesis in human.
CBP and P300 are critical for the regulation of distinct gene subsets. To gain insights into the common 
and divergent involvement of CBP and p300 in the gene regulation underlying myogenesis, we compared at four 
Figure 1. Human Primary myoblasts (HPMs) differentiate into myotubes and properly express myogenic 
factors. (a) Phase contrast photographs of proliferating HPMs, HPMs at the induction of differentiation (T0), 
HPMs after 24 (T24), 48 (T48) and 72 (T72) hours of differentiation. (b) Western blots of HPM cell extracts 
in proliferation (P) or at the indicated differentiation time points with antibodies recognizing CBP, P300, the 
myogenic factors/markers MYF5, MYOGENIN, MEF2C and MHC as well as the loading control VINCULIN. 
(c) Relative expression of CBP, P300, MYOD, MYOGENIN (MYOG), MEF2C, MHC, CKM transcripts to 
GAPDH expression as measured by quantitative PCR in proliferating HPMs or in HPMs at different time points 
of differentiation as indicated. Graphs show mean ± SD values from three independent experiments.
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time points of HPM differentiation the transcriptomes of cells in which CBP, P300 or both were knocked-down 
by siRNA, with that of control cells. The lists of genes specifically regulated by CBP and/or P300 were generated 
using a threshold of 1.8 fold change relative to the corresponding time point of siRNA control (siCTR)-transfected 
HPMs (Supplementary Tables S1). Transcriptomics data were validated by RT-qPCR for a number of transcripts 
(Supplementary Fig. S3). We found that the expression of more than 3,000 genes was altered for at least one of the 
four time points after induction of differentiation in cells transfected with either siCBP or siP300 (Supplementary 
Figure 2. Impact of CBP or P300 knockdown on HPM differentiation and on myogenic factor expression. (a) 
Phase contrast photographs of non-transfected HPMs (NT) or HPMs transfected with either a control siRNA 
(siCTR) or siRNAs directed against CBP (siCBP) or against P300 (siP300) after different times of transfection 
24 h (T24), 48 h (T48), 72 h (T72) and 96 h (T96), corresponding to 0 h, 24 h, 48 h and 72 h of differentiation, 
respectively. (b) Upper panel: western blot showing the expression of CBP and P300 at different times of 
transfection as indicated after knockdown of CBP or P300. GAPDH was used as loading control. Lower panels: 
quantitative PCR analyses showing the expression of CBP and P300 transcripts relative to GAPDH expression 
in proliferating HPMs (T0) or in HPMs after siCTR, siCBP or siP300 transfection, at different time points 
after transfection as indicated. Graphs show mean ± SD values from at least three independent experiments 
(lower panel). (c) Relative expression of MYOD, MYF5, MYOG, MEF2C, CKM and MHC transcripts to 
GAPDH expression by quantitative PCR in proliferating HPMs (T0) or in HPMs after siCTR, siCBP or siP300 
transfection, at different time points of transfection as indicated. Graphs show mean ± SD values from at 
least three independent experiments. Statistical significance are relative to siCTR and were calculated with an 
unpaired t-test; ns: not significant; *p < 0.05, **p < 0.01.
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Tables S1). Differentially expressed genes were then classified to discriminate the effect of CBP and P300 on 
gene expression according to the following criteria: upregulation versus downregulation and common versus 
specific for CBP or P300 (Supplementary Table S2). These lists were further used to build heatmaps at all time 
points of differentiation, illustrating the different categories defined by the above criteria (Fig. 3a–d). As outlined 
from these figures, CBP and P300 mostly regulate distinct gene sets: 1,617 (48%) genes were only affected by 
P300 (Fig. 3d) and 1,048 (31%) were specific to CBP (Fig. 3c), while 623 (19%) genes were commonly affected 
by both factors (Fig. 3a) and 76 (2%) were regulated in an opposite manner (Fig. 3b). Analyzing the number of 
genes affected at each time point confirmed that a high proportion of genes was affected specifically by each HAT 
(Fig. 3e). Indeed, around 75% of the genes regulated by P300 were not shared by CBP and vice versa, and this was 
Figure 3. CBP and P300 regulate common and divergent gene subsets. Heatmaps of (a) genes down- or 
upregulated by CBP and P300, (b) genes regulated in an opposite way by CBP and P300, (c) genes specifically 
down- or upregulated by CBP, (d) genes specifically down- or upregulated by P300. (e) Number of genes down- 
or upregulated by either CBP or P300 or both at different transfection time points. (f,g) Proportion of genes 
activated (f) or repressed (g) during HPM differentiation that are affected by CBP or P300 knockdown.
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true independently of the time point considered and if the genes were up- or downregulated during differentia-
tion (Fig. 3e). These results support the idea that CBP and P300 are redundant for the regulation of a small set of 
genes, but that the major fraction of genes requires the selective action of one of these HATs.
To more specifically assess the effect of CBP and P300 on the myogenic differentiation program, we also mon-
itored the effect of CBP and P300 knockdown on the genes that are either activated or repressed during normal 
differentiation (Fig. 3f,g and Supplementary Tables S1). This revealed that, at each time point of differentiation, 18 
to 60% of the activated genes and 5 to 32% of the repressed genes were not properly expressed following CBP or 
P300 knockdown. Thus, in aggregate, both factors are required for the proper expression of ± 40% of genes whose 
expression is modified during HPM differentiation. Of note, CBP and P300 knockdown primarily impaired the 
upregulation of the genes activated during myogenesis, while it caused both activation and downregulation of 
the repressed genes. Hence, CBP and P300 play a critical role in the activation of the human myogenic program.
Next, we compared the genes deregulated by CBP or P300 single knockdown to those affected in the double 
knockdown. Between 52 and 72% and between 38.5% and 62.5% of the genes downregulated in either of the 
single knockdown were also repressed by the double knockdown at any time point (Supplementary Fig. S4a). 
Similarly, 52 to 73% and 44 to 56% of the genes activated in either siP300 or siCBP were commonly upregulated 
in the double knockdown (Supplementary Fig. S4b). Thus, the double knockdown recapitulates the majority of 
the deregulations observed in the single knockdown. Conversely, 35 to 45% or 50 to 59% of the genes respectively 
repressed or activated in the double knockdown were not affected in either of the two single knockdowns, sug-
gesting that their expression is regulated by CBP and P300 in a redundant manner (Supplementary Fig. S4a,b). 
Moreover, consistent with the results obtained with the single knockdowns (Fig. 3e,f), the double knockdown 
compromised the expression of respectively 22 to 68% and 6 to 26% of the genes activated or repressed at the 
different time points of HPM differentiation (Supplementary Fig. S4c). Thus, these data confirm the key role of 
CBP and P300 in the rewiring of gene expression during muscle differentiation and identify a gene population for 
which CBP and P300 may be functionally redundant.
CBP and p300 regulate different components of major cellular processes. To reveal the key bio-
logical processes controlled by CBP and/or P300 in HPMs, gene ontology (GO) analyses were performed with all 
the genes downregulated or upregulated after CBP or P300 knockdown (Supplementary Table S3). A selection of 
the most representative top-scoring GO categories is presented Table 1. In addition, to better define the specific 
and common functions of these two HATs, we built gene networks from the lists of genes that are specifically 
downregulated or upregulated by siCBP or siP300 and that are commonly deregulated by siCBP and siP300 
(Supplementary Fig. S5).
Concerning the upregulated genes, we observed limited GO enrichments and basically no overlap between 
the processes deregulated by CBP or P300 knockdown. Still, siP300 was associated with the induction of genes 
implicated in nucleosome assembly or type I interferon signalling pathway, and siCBP with the induction of 
genes participating in gluconeogenesis (Table 1). Correspondingly, two of the main hubs present in siCBP upreg-
ulated gene network, PPARA and PPARGC1A, are involved in gluconeogenesis19,20 (Supplementary Fig. S5a). 
Moreover, several hubs in the different upregulated gene networks correspond to genes associated with inflam-
matory/immune response; for instance STAT121, EDN122 or IL1523 in siP300, CCL224 or NOTCH125 in siCBP, and 
CXCL1224, EGFR26, FGF227 or TLR328 in siCBP and siP300 (Supplementary Fig. S5a). These data suggest that a 
reduction of P300 and/or CBP could trigger inflammatory conditions. Of interest, the impact of CBP or P300 
seemed independent of apoptosis as no apoptotic gene was upregulated and no GO enrichment related to apop-
totic pathways could be detected in CBP or P300 knockdown conditions (Supplementary Table S3).
Concerning the downregulated genes, we observed a strong over-representation of GO categories related 
to muscle development upon CBP or P300 knockdown, which confirmed the critical role of these two HATs in 
GO-Term
GO-Term 
ID
All siCBP 
down
All siP300 
down
Specific siCBP 
down
Specific siP300 
down
Common siCBP & 
siP300 down
All double 
siRNA down
Specific double 
siRNA down
Muscle structure development GO:0061061 1.42E-12 (69) 5.25E-23. (96) 8.01E-04 (30) 2.63–12 (51) 1.02E-11 (39) 6.28E-38 (142) 8.32E-09 (37)
Actin filament-based process GO:0030029 1.35E-07 (61) 9.22E-11 (76) 2.76E-04 (34) 2.91E-07 (49) 1.14E-04 (27) 7.98E-24 (125) 8.11E-07 (35)
Mitotic cell cycle GO:0000278 1.19E-09 (86) 1.34E-09 (95) n.s. (36) n.s. (45) 3.01E-11 (50) 6.88E-09 (118) n.s. (23)
Chromosome segregation GO:0007059 7.36E-14 (50) 4.67E-11 (49) n.s. (13) n.s. (12) 1.33E-18 (37) 1.36E-06 (49) n.s. (4)
Sarcomere organization GO:0045214 1.07E-04 (9) 5.90E-15 (20) n.s. (2) 9.66E-10 (13) 1.22E-05 (7) 1.12E-20 (27) 2.73E-04 (6)
Cholesterol biosynthetic process GO:0006695 4.71E-11 (19) n.s. (4) 1.24E-11 (16) n.s. (1) n.s. (3) 2.80E-09 (21) n.s. (2)
Extracellular matrix organization GO:0030198 7.91E-04 (28) 1.76E-04 (33) n.s. (15) n.s. (20) n.s. (13) 1.80E-15 (67) 6.32E-09 (26)
GO-Term GO-Term ID All siCBP up All siP300 up Specific siCBP up
Specific siP300 
up
Common siCBP & 
siP300 up
All double 
siRNA up
Specific double 
siRNA up
Type I interferon signalling pathway GO:0060337 n.s. (5) 3.23E-10 (23) n.s. (3) 1.46E-10 (21) n.s. (2) 6.76E-10 (26) n.s. (5)
Positive regulation of gluconeogenesis GO:0045722 2.07E-05 (6) n.s. (1) 2.53E-06 (5) n.s. (0) n.s. (1) n.s. (1) n.s. (1)
Regulation of RNA biosynthetic process GO:2001141 1.57E-05 (172) n.s (234) 9.29E-04 (110) n.s. (172) n.s. (62) 5.12E-10 (372) 3.29E-04 (148)
Table 1. Gene ontology (GO) analysis of the genes down- or upregulated by the CBP or P300 single knockdown 
or by the double knockdown CBP&P300. Top-scoring most representative GOs related to downregulated 
genes by CBP, P300 or CBP&P300 are in bold, while GOs associated with upregulated genes are in italic and 
underlined. P-values are indicated (“n.s.”: not significant/p-value ≥ 10−3) Numbers into brackets represent the 
absolute number of genes.
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the activation of the human myogenic program (Table 1). In addition, both HATs are required for the proper 
expression of genes implicated in mitotic cell cycle or chromosome segregation, as well as in actin filament-based 
process or extracellular matrix adhesion. Of note, most of the top scoring GO terms were associated with both 
siCBP and siP300, whereas only a few GO categories were specifically associated with CBP or P300 knockdown 
(e.g. sarcomere organisation with siP300, cholesterol metabolism with siCBP). Thus, CBP and P300 knockdowns 
essentially lead to the upregulation of genes participating in the same biological processes.
Interestingly, besides the genes commonly regulated by these two HATs in these processes, an important 
fraction of the genes was specifically affected by one or the other (Table 1). For example, out of 61 genes down-
regulated by siCBP that participate in actin filament organisation, 35 are specific to CBP and 26 are common 
with P300. More specifically, among the myogenic factors/markers, MEF2A, MYF6/MRF4, MYOSIN HEAVY 
CHAIN 7 (MYH7) or TROPONIN C2 (TNNC2) were regulated by both CBP and P300, MYOG, MEF2C, MEF2D 
or MYH6 were specifically under the control of P300, and MYH2 or TNNT1 were specifically regulated by CBP 
(Fig. 4a). Of note, the Early Growth Response 1 (EGR1) transcription factor appearing as an important hub in the 
gene network downregulated by siP300 (Supplementary Fig. S5b). EGR1 having been shown recently to induce 
myogenic differentiation by activating Myogenin expression29, our data identify this factor as a new key player in 
muscle differentiation. Similarly to myogenic factors, CBP and P300 seem to act in a complementary manner to 
control components of the replication machinery: CBP controls CDC45 and the GINS (Go-Ichi-Ni-San) complex, 
while P300 regulates RFC (Replication Factor C) and PCNA (Proliferating Cell Nuclear Antigen) (Fig. 4b). For 
cell cycle progression, CBP controls E2F1 and CDK4 expression while P300 regulates RB and CYCLIN D leading 
in both cases to the regulation of E2F target genes and thus to the G1/S transition arrest. Moreover, both CBP and 
P300 inhibit the G2/M transition by regulating FOXM1, CYCLIN A and CDK1 expression (Fig. 4b). Consistent 
with a key role for these two HATs in the control of cell cycle progression, E2F1/CDK4, RB1 and CDK1/FOXM1 
appeared as important hubs in the downregulated gene networks of siCBP, siP300 and of both siCBP and siP300, 
respectively (Supplementary Fig. S5).
Our analyses also revealed that CBP and P300 are required for the proper expression of several factors impli-
cated in cell adhesion, notably within the Dystrophin-Glycoprotein complex and the α7β1 Integrin complex, 
which are often deregulated in human dystrophies (Fig. 5) (for a review30). While both CBP and P300 regulate 
the expression of sarcomeric proteins like MYH7, Tropomodulin, Troponin C2 (TNNC2), Myotilin, α-Actinins 
and of a number of proteins belonging to the upstream complexes such as Integrin α7, Melusin, or Sarcoglycan γ, 
they also regulate distinct genes. This is the case for Collagen type XI, Talin, Plectin, Syncoilin, MYH6, Troponin T1 
for CBP while P300 regulates among others, Nebulin, Elastin, Fibrillin, Laminin α2, Biglycan, MYH6, Sarcoglycan 
δ and Dystrophin (Fig. 5). Hence, by impairing the expression of these factors, CBP and P300 knockdowns could 
lead to the development of dystrophic phenotypes.
In sum, it appears that CBP and P300 act on the same processes in part by controlling complementary sets 
of genes. Our results also point out that the role of CBP and P300 in human primary myoblast/myotube extends 
beyond the control of their differentiation and encompasses the control of key biological functions.
To analyse whether these different processes might be directly regulated by CBP and/or P300, we crossed our 
datasets with that of Blum et al. in which they identified in mouse C2C12 cells genome-wide active enhancers and 
their associated genes on the basis of ChIP-seq data with p300, H3K4me1, H3K18ac, H3K27ac –an acetylation 
mark specifically deposited by CBP and P300- and polII31. Thus, these enhancers and associated genes are likely 
direct targets of CBP and/or P300 during myogenic differentiation31. Thereby we could define a list of enhancers/
genes that are likely direct targets of P300 and/or CBP (since they are bound by P300 and/or contain a histone 
mark deposited by CBP or P300) in mouse C2C12 cells undergoing myogenic differentiation. Crossing this list 
of enhancer associated genes with our datasets indicated that among the downregulated genes following siCBP 
or siP300 treatment in HPM, a proportion of 20.6% and 24.6% might represent genes directly activated by CBP 
or P300, respectively (Supplementary Table S4). Interestingly, GO analyses of these “direct” genes revealed that 
muscle structure development, actin filament-based process, cholesterol biogenesis and adhesion processes are 
significantly enriched and thus, most likely directly regulated by CBP and/or P300, while cell cycle regulation, 
chromosome segregation and sarcomere organization are probably regulated indirectly by the two coactivators. 
On other hand, the same analyses performed with genes upregulated upon siCBP or siP300 did not show any 
significant enrichment in GO related to inflammation, gluconeogenesis or RNA biogenesis (Supplementary 
Table S4). Thus, these upregulated processes are most likely controlled indirectly by CBP and P300. Indeed, a lot 
of late-time changes in gene expression and especially upregulated genes might be due to the cascade effect of 
genes differentially regulated at earlier times as bona fide targets of CBP/p300 inhibition.
CBP and P300 are redundant for gene subsets. Next, we focused on the genes that were only deregulated 
following P300 and CBP double knockdown and that likely reflect the redundant role of these HATs. Besides GO 
categories already enriched in either of the single knockdown such as muscle structure development (Table 1), 
siCBP&siP300-dependent downregulated genes were most strongly associated with extracellular matrix organ-
isation and cell adhesion (Table 1), suggesting that the level of redundancy between CBP and P300 in HPMs 
is particularly strong for these two processes (Fig. 5). Notably, CBP and P300 are redundant for the expression 
of at least 6 collagens, 10 matrix metalloproteinases (MMPs), 3 intercellular adhesion molecules (ICAMs) and 
2 integrins (Supplementary Table S3). Moreover, the gene regulatory network downregulated after the double 
knockdown siCBP&siP300 highlighted MYC and AGT as two prominent hubs (Supplementary Fig. S6a). MYC 
has been identified as a major factor that is responsible for the synthetic lethality observed in CBP-deficient cells 
after ablation of P30032. Similarly, AGT expression has been shown to require both CBP and P30033. These obser-
vations reinforce the validity and the interest of our knockdown approach.
Concerning the genes solely upregulated after the double knockdown of CBP and P300, no strong GO enrich-
ment was observed (Tables 1 and S3). Nevertheless, the corresponding gene network (Supplementary Fig. S6b) 
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identified several hubs of genes that are involved in apoptosis, like BAX (Bcl2-Associated X)34, miR-34A35 and 
PRKCD (Protein Kinase C Delta)36 or in innate immunity/inflammation such as IKBKE (Inhibitor of Nuclear 
Factor Kappa B Kinase Subunit Epsilon)37 and CEBPD (CCAAT/Enhancer Binding Protein Delta)38. HDAC1 also 
came out as a major hub and could in this context, either trigger cell cycle arrest and senescence39 or be involved 
in inflammation40.
These data underscore the redundant role of CBP and P300 in promoting cell survival as well as in the regula-
tion of muscle cell attachment.
Decreased CBP and P300 HAT activities in Zebrafish leads to a muscular dystrophy-like pheno-
type. To analyze in vivo whether and to which extend CBP and P300 regulate muscle adhesion/attachment/
integrity, we made use of the zebrafish model, which has become instrumental to address whether the loss of com-
ponents contributes to muscle physiology and pathology41. Indeed, zebrafish dystrophic mutants and morphants 
with skeletal muscle abnormalities represent informative models of muscle disease pathogenesis and therapy41–43. 
In most of these mutants, skeletal muscle development appears normal but the first contractions trigger muscle 
cell detachment from their insertion site, which is followed by myotome degeneration42. Accordingly, the detach-
ment of muscle fibers is a common feature of several dystrophic mutants and/or morphants.
Figure 4. Impact of CBP and P300 knockdown on myogenesis, replication and cell cycle regulation. (a) 
Simplified schema showing the different steps of myogenesis and the impact of CBP and/or P300 on the 
corresponding myogenic factors/markers. Schema adapted from15. (b) Schematic representations of DNA 
replication and the factors under the control of CBP and/or P300, after77 (upper panel) and of cell cycle 
progression, after78 (lower panel). (a,b) Red dots, blue dots and green dots label factors whose transcripts are 
downregulated by CBP, P300 or the double CBP&P300 knockdown, respectively.
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To inhibit CBP and P300 HAT activities in fish, embryos were treated with increasing concentrations of C646, 
a specific CBP/P300 HAT inhibitor44, and the resulting phenotypes were analyzed. We found that the addition of 
C646 resulted in a muscular dystrophy-like phenotype at 6 days of development, i.e. embryos showed a trunk/tail 
curvature concomitant with muscle fiber detachment (Fig. 6a–c). Moreover, the addition of methylcellulose to 
increase water viscosity led to a more dramatic detachment/disorganization of the somites in zebrafishes exposed 
to a low amount of C646, further validating the dystrophic nature of the phenotype (Fig. 6c–g). This phenomenon 
was not due to apoptosis as we did not detect any increase of cleaved caspase 3 expression by immunofluorescence 
(Fig. S8), and the expression of the anti-apoptotic gene bcl2 or of the pro-apoptotic genes bax and puma was not 
affected upon CBP/P300 inhibition, as revealed by RT-qPCR (Fig. S8). Of note, CBP/P300 HAT activity was effi-
ciently reduced in these conditions as assessed by the dose-dependent decrease of H3K27 and p53 acetylation, 
two well-established substrates of CBP and P30045 (Fig. 6h–m).
Finally, we checked by RT-qPCR whether the inhibition of P300 and CBP in zebrafish also affected the expres-
sion of the integrin- and dystrophin-associated adhesion complexes as observed in human primary myoblasts 
(Fig. 6n). Strikingly, all the genes tested that were downregulated in HPMs following CBP and/or P300 knock-
down, were also repressed in C646-treated zebrafish. Moreover dystroglycan (dag1), whose expression was not 
affected by either CBP or P300 in human cells (Fig. 5), was not deregulated either by C646 in zebrafish (Fig. 6n). 
Altogether these data indicate a strong impact of CBP and P300 on myogenic cell adhesion in human cells and in 
zebrafish and suggest that a reduction in the enzymatic activity of these co-activators leads to a dystrophic pheno-
type in zebrafish and potentially in human cells.
Figure 5. Impact of CBP and P300 knockdown on cell adhesion. CBP and P300 regulate the expression of 
proteins belonging to the integrin- and dystrophin-associated glycoprotein complexes, from the extracellular 
matrix to the sarcomere. Red dots, blue dots and green dots label factors whose transcripts are downregulated 
by CBP, P300 or the double CBP&P300 knockdown, respectively. Adapted from79–81.
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Figure 6. P300/CBP histone acetyltransferase activity inhibition induces muscle cells detachment in zebrafish. 
(a–c) Confocal projections of transgenic Tg(smyhc1:EGFP)i104 embryos treated with either DMSO (vehicle), 
2 μM or 3.5 μM C646 at 10 hpf for 24 h, fixed and imaged at 6 dpf. (a’–c’): higher magnification views of the 
boxed area in a–c. Arrowheads indicate muscle cell attachment abnormalities. (d–g) Confocal projections 
of transgenic Tg(smyhc1:EGFP)i104 embryos treated with either DMSO or 2 μM C646 from 10 hpf for 24 h, 
and further raised in water (−Methylcellulose; d,e) or in viscous medium (+Methylcellulose; f,g) until 5 dpf. 
(h–m) Immunostaining against either H3K27ac (h–j) or p53ac (k–m). Confocal sections of embryos treated 
with either DMSO (vehicle), or 2 μM or 3.5 μM C646 at 10 hpf for 10 h and fixed at 20 hpf, as indicated on the 
panels. Fluorescent intensity is color-coded. (n) Relative mRNA expressions were determined by RT-qPCR in 
3 dpf embryos treated with either DMSO, or 2 μM or 3.5 μM C646 from 10 hpf for 24 h. Error bars represent 
S.D. Statistical significance is relative to control and was calculated with an unpaired t-test. ns: not significant; 
*p < 0.05, **p < 0.01, ***p < 0.001. A minimum of 12 embryos were analysed per condition.
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Discussion
Here, we assessed and compared the role of CBP and P300 during myogenesis at a global scale in human primary 
myoblasts. In sum, our data show that these two related factors control human myogenesis by regulating essen-
tially distinct gene networks and highlight an unforeseen link between CBP/P300 activity and the emergence of 
dystrophic phenotypes.
To characterise CBP and P300 function in myogenesis, we used an siRNA-mediated knockdown strategy 
in human primary myoblasts. SiRNA approach was chosen rather than CRISPR/CAS9 as the knockout of CBP 
or P300 inhibited cell proliferation and triggered cell death by mitotic catastrophe46. In addition, knowing the 
limitations of ChIP-sequencing data with CBP and P300 and in particular the poor correlation between CBP/
P300 binding and expression of the nearest gene7, we did not look for direct CBP or P300 target genes but rather 
assessed at global scale the transcriptional or post-transcriptional consequences of CBP and/or P300 knockdown 
using microarrays. However, merging our data with genes associated with active enhancers -that bound P300 or 
were enriched in H3K27 acetylation mark and could thus be direct targets of CBP and/or P300- identified previ-
ously in C2C12 cells31 indicated that while processes such as myogenic differentiation, actin filament formation, 
cholesterol metabolism and adhesion complex were most likely regulated directly by CBP and/or P300, upregu-
lated pathways were probably a consequence of the cascade effect of genes differentially regulated at earlier times 
as bona fide targets of CBP and/or p300 inhibition.
Due to their high sequence homology47, these two proteins have often been referred to as CBP/P300 since 
their identification, and their activity has commonly been considered as largely redundant. By comparing the 
knockdown of each of these two factors and their concomitant knockdown, we bring new insights into the redun-
dant and the divergent function(s) of CBP and P300. Our results clearly show that these two factors chiefly reg-
ulate distinct gene sets to control several aspects of HPM biology, even though they also exhibit some degree of 
redundancy.
Our phenotypic analysis indicates that the knockdown of CBP or P300 is not sufficient to prevent the early 
steps of myogenic differentiation (i.e. elongation and myotube fusion) but eventually alters muscle develop-
ment and causes muscle cell detachment. Actually, both factors are essential for the deployment of the myogenic 
transcriptional program, each of them controlling the activation of a subset of myogenic factors and markers, 
which collectively represent around half of the genes upregulated during HPM differentiation. A previous study 
showed that while P300 HAT activity was required for myogenesis in mouse embryos and embryoid bodies, 
CBP HAT activity appeared dispensable48. The difference between these results and ours might have several rea-
sons. Notably, CBP and P300 HAT mutants behave as dominant negative48 and might thus cross-interfere with 
each other. Along that line, myf5 expression, which is impaired in mouse mutants for P300 HAT activity48, was 
only affected in human primary myoblasts following the CBP and P300 double knockdown. Moreover, some 
HAT-independent functions for CBP have been described49,50. Finally, these discrepancies might reflect species 
or stage-specific differences. For example, it has been shown that myogenin plays distinct functions in mouse 
embryos and during post-natal life51. As human primary myoblasts were collected from adults, their differenti-
ation probably recapitulates adult muscle growth and regeneration rather than embryonic myogenesis. Thus, in 
light of our results, we conclude that both CBP and P300 play an essential role in the activation of the adult muscle 
transcriptional program in human.
In addition to the regulation of muscle specific genes, our transcriptomic analyses highlight the role of CBP 
and P300 in the control of genes implicated in cell cycle and replication. In line with these results, it has been 
reported in other cell systems that CBP and P300 regulate replication52 and cell cycle progression53 and that C646 
inhibits these processes54. Interestingly, our data suggest that they regulate cell cycle and replication in a comple-
mentary manner since we identified specific targets for CBP and P300 in these two processes.
Besides CBP and P300 specificity, the knockdown of both CBP and P300 revealed that they also play a redun-
dant role for the regulation of certain genes. The two main categories of genes downregulated specifically upon 
CBP/P300 double knockdown correspond to muscle system and extracellular matrix organisation, which are also 
deregulated in single knockdown conditions. These two processes are thus targeted at multiple levels by CBP and 
P300. Moreover, the main hubs/genes upregulated after the double knockdown of CBP and P300 are implicated 
in apoptosis, suggesting that CBP and P300 play a major redundant role in cell protection and survival, which is 
consistent with the synthetic lethality recently described between CBP and P300 in cancer cells32. Of note, CBP/
P300 double knockdown also caused an upregulation of HDAC1, which has been involved in inflammation and 
immune response40, but also in the repression of the myogenic program by modulating the transcriptional activ-
ity of MyoD55,56. Similarly, another histone deacetylase, SIRT3, which was shown to block myofibroblast differen-
tiation57, and the methyltransferase G9a/EHMT2 (Euchromatic Histone Methyltransferase 2), which was found 
to inhibit adult myogenesis/regeneration58–61, were also upregulated. Hence, CBP and P300 knockdown promotes 
the expression of several epigenetic modifiers that might impair myogenesis.
Finally, we found that CBP and P300 downregulation in adult myoblasts leads to muscular dystrophy fea-
tures. Indeed, one striking phenotype associated with CBP or P300 knockdown in differentiation-induced HPMs 
consisted in the massive detachment of the muscle fibers from the culture plate. Consistent with this, CBP and 
P300 were both required for the expression of several factors involved in cell adhesion, including components 
of the extracellular matrix, the sarcolemma and the cytoskeleton. In humans, muscular dystrophies include a 
heterogeneous group of genetic diseases leading to muscle degeneration and impaired function. Mutations of 
more than 30 genes give rise to various types of muscular dystrophies, which differ in severity, age of onset and 
muscle groups affected62. Mutations in the Dystrophin gene cause Duchenne and Becker muscular dystrophies, 
while mutations in Sarcoglycan are responsible for some forms of limb girdle muscular dystrophies63. Mutations 
in Integrin α7 gene cause congenital myopathy64 and the most common form of congenital muscular dystrophy 
type 1 A (MDC1A) is associated with loss of functional Laminin α265. We found that the knockdowns of CBP 
and/or P300 downregulated all afore mentioned genes and activated the expression of several genes associated 
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with an inflammatory response, another characteristic feature of muscular dystrophies66. Interestingly, it has 
been shown that impaired muscle structure due to the absence of intracellular or extracellular structural com-
ponents results in cell membrane instability, initiating a cascade of deleterious events such as apoptosis, necro-
sis and inflammation62. Strikingly, upon inhibition of CBP and P300 HAT activity in zebrafish, skeletal muscle 
development appeared normal but the first contractions triggered muscle cell detachment. This finding is similar 
to the phenotype reported for zebrafish dystrophic mutants and morphants41–43. Moreover, we recently showed 
that the enforced expression of CBP prevented muscle detachment in a zebrafish model of Duchenne muscular 
dystrophy67. Therefore CBP and P300 seem critical to sustain muscle integrity in vivo. On the opposite, previous 
studies have shown that deacetylase inhibitors (HDACi) can ameliorate dystrophic phenotypes by promoting 
myogenesis and regeneration in dystrophic muscles (for a review68). At the molecular level, follistatin (Fst) upreg-
ulation by HDACi was found to be responsible for boosting regeneration in dystrophic muscles69,70. Interestingly 
we observed that CBP or P300 knockdown decreases follistatin expression. Until now, a pharmacological treat-
ment that cures muscle dystrophies still needs to be discovered. Epigenetic drugs such as HDACi, target the 
downstream effects of the genetic expression defects of Dystrophin or -α-sarcoglycan, but only slow down disease 
progression. It is tempting to speculate that the combination of HDACi with activators of CBP and P300 acetyl-
transferases activities71 could synergize to rescue muscle integrity and strength in muscular dystrophic diseases. 
These data highlight an unforeseen link between CBP/P300 activity and the emergence of dystrophic phenotypes 
and identify CBP and P300 as key mediators of adult muscle integrity, suggesting a new lead for intervention in 
muscular dystrophy.
Materials and Methods
Cell culture conditions. Primary human myoblasts were isolated from skeletal muscles of donors as pre-
viously described72. Purified myoblasts were plated in Petri dishes and cultured in growth medium containing 
Dulbecco’s Modified Eagle’s Medium (Gibco) supplemented with 20% foetal bovine serum (FBS) (GE Healthcare, 
PAA), 0.5% Ultroser G serum substitute (PALL life sciences) and 50 µg/ml Gentamicin (Thermo Scientific) at 
37 °C in humidified atmosphere with 5% CO2. All experiments were carried out between Passage 4 (P4) and P8 
to avoid cell senescence. Myogenic differentiation of confluent cells was induced by changing growth medium to 
DMEM containing 2% FBS and 50 µg/ml Gentamicin (differentiation medium).
Ethics approval and consents. Human Primary myoblasts were collected in the Centre Hospitalier 
Universitaire Lapeyronie (Montpellier, France) from donors after obtention of their informed consent. All exper-
iments were performed in accordance with the Declaration of Helsinki and approved by the ethical committee of 
the Hospital of Montpellier (France). Samples were approved for storage by the French “Ministère de l’Enseigne-
ment et de la Recherche” (N°DC-2008-594).
Zebrafish embryos were handled in a facility certified by the French Ministry of Agriculture (approval ID 
A-31-555-01) and in accordance with the guidelines from the European directive on the protection of animals 
used for scientific purposes (2010/63/UE), French Decret 2013–118. All experimental procedures were approved 
by the ethical committee of the “Ministère de l’Enseignement Superieur et de la Recherche et de l’Innovation” 
(approval number APAFiS#7124-2016100517263944v3).
siRNA transfections. Myoblasts (0.25.106 cells) were plated in 60 mm Petri dishes and cultured in growth 
medium for 48 h before being transfected with 5 nM siRNA using Lipofectamine RNAiMAX (Invitrogen) accord-
ing to manufacturer’s instructions. Cells were harvested by scraping either at 24 h after transfection (T0) or at 24 h, 
48 h and 72 h after induction of differentiation corresponding to T48, T72 and T96 from transfection time. Target 
sequences of siRNAs duplexes used are listed in supplementary methods.
RNA extraction and transcriptome analysis. Total RNAs were extracted from cells using Aurum Total 
RNA Mini Kit (Bio-rad) according to manufacturer’s instructions and eluted in RNAse-free water. Biotinylated 
single strand cDNA targets were prepared, starting from 150 ng of total RNA, using the Ambion WT Expression 
Kit and the Affymetrix GeneChip® WT Terminal Labelling Kit according to Affymetrix recommendations. 
Following fragmentation and end-labelling, 3 µg of cDNAs were hybridized for 16 h at 45 °C on GeneChip® 
Human Gene 2.0 ST arrays (Affymetrix) interrogating over 400,000 RefSeq transcripts and ~ 11,000 LncRNAs 
represented by approximately 27 probes spread across the full length of the transcript. The chips were washed and 
stained in the GeneChip® Fluidics Station 450 (Affymetrix) and scanned with the GeneChip® Scanner 3000 7 G 
(Affymetrix) at a resolution of 0.7 µm. Raw data (.CEL Intensity files) were extracted from the scanned images 
using the Affymetrix GeneChip® Command Console (AGCC) version 3.2. CEL files were further processed 
with Affymetrix Expression Console software version 1.3.1 to calculate probe set signal intensities using Robust 
Multi-array Average (RMA) algorithms with default settings. The significance threshold for the dataset was cal-
culated using a manual biostatistics analysis derived from Lenth’s pseudo standard error method61. Briefly, fold 
change values relative to siCTR were calculated at each time point and the values were ordered from the lowest 
(1 = no change) to the highest. Gene numbers were plotted on the x-axis and fold values were plotted on the 
y-axis. All values that departed from linearity were judged as significant. In order to determine a suitable cut off 
value for our datasets, we calculated average fold changes every 100 genes and the slopes of the corresponding 
curves. Fold changes were plotted on the x-axis and slopes on the y-axis. This showed that, depending on the 
siRNA treatment and the differentiation time point, the fold change values significantly departed from linearity 
from 1.5 to 1.75. Therefore, we chose 1.8 and used this value as our unique significance threshold for all our 
datasets. Of note, genes showing a significant change in expression between non-transfected (NT) cells and cells 
transfected with the control siRNA (siCTR) were not included in the present analysis to avoid effects due to the 
transfection itself and not the CBP and/or p300 knockdown.
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Heatmaps and gene networks construction. Lists of genes specifically regulated by CBP and/or P300 
and by the double knock down of CBP and P300 were generated using a fold change of 1.8 relative to the corre-
sponding time point transfected with the control siRNA (Table S1). These lists were subdivided in 4 cases on the 
basis of the influence of CBP and/or P300 knockdown, then classified on the basis on the gene expression levels 
(Hierarchical clustering) under the MeV environment73. Gene networks were created with Genomatix Pathway 
System (GePS) (www.genomatix.de) using a cut off of p-value < 10−3 for “pathway based networks” and “signal 
transduction networks” categories. The top-100 interacting genes were recovered and these interactions lists were 
then imported into Cytoscape version 3.6.0 (cytoscape.org)74 to visualize the networks and the hubs using the 
prefuse force directed layout. Node sizes and labels were based on the degree of connectivity of the nodes. Hence, 
larger nodes represent network hubs.
Reverse transcription and real-time PCR. 1 µg total RNA was converted into cDNA using iScript cDNA 
Synthesis Kit (Bio-rad) with Oligo(dT) and random hexamer primers for 30 min at 42 °C according to manufac-
turer’s instructions. cDNA were then diluted 20-fold and quantified by qPCR using SsoFast Evagreen Supermix 
(Bio-rad) and sequence specific primers. Data were acquired on CFX96 Real-Time System (Bio-rad). Samples 
were analyzed in triplicates and the expression level was calculated relative to GAPDH for human cDNA and to 
EF1α for zebrafish samples. Sequences of primer pairs used in gene expression analysis are listed in supplemen-
tary methods.
Protein isolation and Western-blot analyses. Cells were lysed in Protein extraction buffer (50 mM 
Tris pH 8, 150 mM NaCl, 0.5% NP40 and 1 mM EGTA) and protein concentrations were determined using 
the Bio-Rad DC Protein Assay reagents package (Bio-rad). A total of 40 µg of total proteins were separated by 
SDS-PAGE and transferred to Nitrocellulose membranes, blocked 1 h at room temperature (10% milk, 0.1% 
Tween-20 TBS) and probed at 4 °C overnight (2% milk, 0.1% Tween-20 TBS) with the following primary anti-
bodies: anti-CBP (sc-369, Santa Cruz Biotechnology); anti-P300 (sc-585, Santa Cruz Biotechnology); anti-Myf5 
(sc-302, Santa Cruz Biotechnology); anti-Myogenin (sc-576, Santa Cruz Biotechnology); anti-Mef2C (sc-
13266, Santa Cruz Biotechnology); anti-Vinculin (sc-5573, Santa Cruz Biotechnology) and anti-MHC (MF20, 
Developmental Studies Hybridoma Bank). After washings, membranes were incubated with horseradish 
peroxidase-conjugated secondary antibodies for 1 h. Detection was performed using Lumi-lightplus Western 
Blotting substrate (Roche) according to manufacturer’s instruction. Original scans of all western blots shown in 
this study can be found in Supplementary Fig. S7.
Zebrafish lines and embryo injections. Zebrafish transgenic line Tg(smyhc1:EGFP)i10475 was maintained 
on wild-type background. Staging and husbandry were as described76.
Embryos were treated with 2 μM or 3.5 μM of C646 CBP/P300 inhibitor (Calbiochem) or with DMSO for 
different periods of time as indicated. Immunohistochemistry experiments were performed as followed. Embryos 
were fixed with 4% paraformaldehyde (PFA)/PBS overnight at 4 °C, then washed twice with Phosphate Buffered 
Saline/1% Triton X-100 (PBST), permeabilized with PBST/0.5% Trypsin for 30 sec (>20 hpf embryos) or for 
1 min (>48 hpf embryos) and washed twice again with PBST. After blocking with PBST/10% Foetal Calf Serum 
(FCS)/1% bovine serum albumin (BSA) (hereafter termed ‘blocking solution’) for at least 1 h, embryos were incu-
bated with antibodies directed against either GFP (Torrey Pine, Biolabs), or acetyl-H3K27 (Abcam), or acetyl-p53 
(Cell Signalling Technology) or cleaved Caspase-3 (Asp175) (Cell Signaling Technology) in blocking solution 
overnight at 4 °C followed by washing five times with PBST. Embryos were then incubated with the appropriate 
Alexa Fluor-conjugated secondary antibodies (Molecular Probes) for at least 2 h at room temperature and washed 
three times. Nuclei were then stained with TO-PRO3 (Molecular Probes) and washed twice with PBST. Embryos 
were dissected, flat-mounted in glycerol and images were recorded on a confocal microscope (TCS SP8, Leica 
Microsystems) with an L 25 × /0.95 W FLUOTAR VISIR objective (zoom X1.25) using the scanner resonant 
mode.
Data availability. The microarray data from this study were submitted and approved by the National Center 
for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database. They are available under the 
accession number GSE94006.
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